PER 1.35% 7.5¢ percheron therapeutics limited

Commercial success is limited by not having enough money to...

  1. 720 Posts.
    lightbulb Created with Sketch. 210
    Commercial success is limited by not having enough money to throw at trials. If they could have raised $70-$100 mill (no problem for Sarepta), we’d be nearing completion of the original pivotal trial.

    IMO has more to do with structure of ANP (and that it doesn’t have new drugs in internal development) than managerial competence, though our history doesn’t help.


 
watchlist Created with Sketch. Add PER (ASX) to my watchlist
(20min delay)
Last
7.5¢
Change
0.001(1.35%)
Mkt cap ! $67.61M
Open High Low Value Volume
7.7¢ 7.8¢ 7.4¢ $24.63K 325.4K

Buyers (Bids)

No. Vol. Price($)
2 142779 7.3¢
 

Sellers (Offers)

Price($) Vol. No.
7.5¢ 8181 1
View Market Depth
Last trade - 16.10pm 26/07/2024 (20 minute delay) ?
PER (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.